Key facts
- It has raised $4.2M across 1 recorded rounds; the latest was Seed Round ($4.2M) in Jun 2025.
- Notable investors include Hummingbird Ventures, Fusion Fund, Compound (New York), Ananda Impact Ventures.
- Pheiron has filed 1 Form D with the SEC, most recently Jun 2025 ($4.2M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Pheiron
Funding rounds
1 roundsAbout Pheiron
Developer of a phenotyping platform designed to decode disease to advance new therapies. The company's platform generates digital biomarkers for the interpretation of biomedical data, transforms complex biomedical data into actionable insights, and develops drugs for rare illnesses, enabling clients to get drugs for different targeted diseases.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2023
- Employees
- 9
- Website
- pheiron.com/
- Ownership
- Privately Held (backing)
Pheiron doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pheiron shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pheiron in its N-PORT filings yet. We sweep new filings monthly.